ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
The Lancet Respiratory Medicine
◽
10.1016/s2213-2600(18)30500-9
◽
2019
◽
Vol 7
(4)
◽
pp. 347-357
◽
Cited By ~ 43
Author(s):
Natasha B Leighl
◽
Matthew D Hellmann
◽
Rina Hui
◽
Enric Carcereny
◽
Enriqueta Felip
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 1 Study
◽
Open Label Phase
Download Full-text
Related Documents
Cited By
References
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
The Lancet Oncology
◽
10.1016/s1470-2045(16)30098-5
◽
2016
◽
Vol 17
(7)
◽
pp. 883-895
◽
Cited By ~ 543
Author(s):
Scott J Antonia
◽
José A López-Martin
◽
Johanna Bendell
◽
Patrick A Ott
◽
Matthew Taylor
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
Download Full-text
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
The Lancet Oncology
◽
10.1016/s1470-2045(21)00247-3
◽
2021
◽
Author(s):
Justin F Gainor
◽
Giuseppe Curigliano
◽
Dong-Wan Kim
◽
Dae Ho Lee
◽
Benjamin Besse
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
Download Full-text
Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
The Lancet Oncology
◽
10.1016/s1470-2045(16)30392-8
◽
2016
◽
Vol 17
(12)
◽
pp. 1683-1696
◽
Cited By ~ 163
Author(s):
Scott N Gettinger
◽
Lyudmila A Bazhenova
◽
Corey J Langer
◽
Ravi Salgia
◽
Kathryn A Gold
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
Download Full-text
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
The Lancet Oncology
◽
10.1016/s1470-2045(16)30565-4
◽
2017
◽
Vol 18
(1)
◽
pp. 42-51
◽
Cited By ~ 226
Author(s):
Charles M Rudin
◽
M Catherine Pietanza
◽
Todd M Bauer
◽
Neal Ready
◽
Daniel Morgensztern
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Antibody Drug Conjugate
◽
Open Label
◽
Phase 1 Study
◽
Open Label Phase
◽
Antibody Drug
Download Full-text
Activity and safety of ceritinib in patients with ALK -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
The Lancet Oncology
◽
10.1016/s1470-2045(15)00614-2
◽
2016
◽
Vol 17
(4)
◽
pp. 452-463
◽
Cited By ~ 229
Author(s):
Dong-Wan Kim
◽
Ranee Mehra
◽
Daniel S W Tan
◽
Enriqueta Felip
◽
Laura Q M Chow
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 1 Trial
◽
Open Label Phase
Download Full-text
Faculty Opinions recommendation of Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.727089160.793540672
◽
2017
◽
Author(s):
Barry Nelkin
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Antibody Drug Conjugate
◽
Open Label
◽
Phase 1 Study
◽
Open Label Phase
◽
Antibody Drug
Download Full-text
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
The Lancet Oncology
◽
10.1016/s1470-2045(13)70142-6
◽
2013
◽
Vol 14
(7)
◽
pp. 590-598
◽
Cited By ~ 379
Author(s):
Takashi Seto
◽
Katsuyuki Kiura
◽
Makoto Nishio
◽
Kazuhiko Nakagawa
◽
Makoto Maemondo
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
Download Full-text
Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial
Lung Cancer
◽
10.1016/j.lungcan.2019.07.007
◽
2019
◽
Vol 135
◽
pp. 66-72
◽
Cited By ~ 5
Author(s):
Dong-Wan Kim
◽
Dae Ho Lee
◽
Ji-Youn Han
◽
Jongseok Lee
◽
Byoung Chul Cho
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
T790m Mutation
◽
Open Label Phase
◽
Anti Tumor Activity
Download Full-text
445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK +) non-small cell lung cancer (NSCLC) previously treated with crizotinib
Annals of Oncology
◽
10.1016/s0923-7534(21)00603-7
◽
2016
◽
Vol 27
◽
pp. ix143
Author(s):
L. Zhang
◽
Y. Shi
◽
D.S.W. Tan
◽
B. Hu
◽
L. Xiaoqing
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Phase 1
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Multicenter Phase
◽
Previously Treated
Download Full-text
Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: a randomized, open-label, phase I/II trial
Cancer Treatment and Research Communications
◽
10.1016/j.ctarc.2021.100427
◽
2021
◽
pp. 100427
Author(s):
Milada Zemanova
◽
Marketa Cernovska
◽
Libor Havel
◽
Tomas Bartek
◽
Sarka Lukesova
◽
...
Keyword(s):
Lung Cancer
◽
Dendritic Cell
◽
Phase I
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Autologous Dendritic Cell
◽
Small Cell Lung
◽
Open Label
◽
Open Label Phase
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close